Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals

AIDS

Volumn 24, Issue 4, 2010, Pages 545-555

  Landrum, Michael L ^a,b   Hullsiek, Katherine Huppler ^b,c   Ganesan, Anuradha ^b,d   Weintrob, Amy C ^b,d   Crum Cianflone, Nancy F ^b,e   Barthel, R Vincent ^f   O'Connell, Robert J ^b,g   Fieberg, Ann ^b,c   Chun, Helen M ^e   Marconi, Vincent C ^a,b   Dolan, Matthew J ^a   Agan, Brian K ^b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Hepatitis B vaccine; Hepatitis B virus; Human immunodeficiency virus; Immunization; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; VACCINATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MILITARY PERSONNEL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, VIRAL; UNITED STATES; YOUNG ADULT;

EID: 77649242444     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832cd99e     Document Type: Article

References (54)

1. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571-577.
2. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 2005; 19:221-240.
3. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23:125-136.
4. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991; 4:416-420.
5. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
6. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926
7. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons-2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002; 51:1-40.
8. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR 2005; 54:1-30.
9. Centers for Disease Control and Prevention. Recommended adult immunization schedule: United States, October 2006-September 2007. MMWR 2006; 55 Q1-Q4.
10. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006; 55:1-25.
11. Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4R lymphocyte count and vaccination schedule. Int J STD AIDS 1996; 7:490-494.
12. Mannucci PM, Zanetti AR, Gringeri A, Tanzi E, Morfini M, Messori A, et al. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 1989; 149: 1333-1337.
13. Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for excellence in adolescent care and health. J Adolesc Health 2001; 29:123-129.
14. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8:558-559.
15. Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6:509-510.
16. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101-105.
17. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable HIV plasma RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41:1045-1048.
18. Fonseca MO, Pang LW, Cavalheiro N, Barone AA, Lopes MH. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard to a double dose. Vaccine 2005; 23:2902-2908.
19. Quaglio G, Talamini G, Lugoboni F, Lechi A, Venturini L, Jarlais DC, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002; 97:985-992.
20. Ghandi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435-1441.
21. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Predictors of lack of response to hepatitis B vaccination in HIV-infected patients. 44th Annual Meeting of the Infectious Diseases Society of America; 12-15 October, Toronto, Ontario, Canada. Abstract 1199. 2006.
22. Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38:1478-1484.
23. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18:1161-1165.
24. Ristola MA, Vuola JM, Valle M, von Reyn F. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine 2004; 23:205-209.
25. Arrazola MP, de Juanes JR, Ramos JT, Aragon AJ, Garcia de Codes A. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol 1995; 45:339-341.
26. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19:1473-1479.
27. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-214.
28. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833-841.
29. Landrum ML, Dolan MJ. Routine vaccination in HIV-infected adults. Infect Dis Clin Pract 2008; 16:85-93.
30. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley KA, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163:454-459.
31. Weintrob AC, Fieberg AM, Agan BK, Ganesan A, Crum-Cian-flone NF, Marconi VC, et al. Increasing age at HIV seroconver-sion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr 2008; 49:40-47.
32. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 2003; 17:2521-2527.
33. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41. http://www.cdc.gov/mmwr/preview/ mmwrhtml/00018871.htm. [Accessed 4 January 2008]
34. DiaSorin Inc. Enzyme immunoassay for the detection of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma [package insert]. Stillwater, MN: DiaSorin, Inc.; 2005. pp. 1-30.
35. Huppler Hullsiek K, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biosta-tistics 2002; 4:179-193.
36. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:14-55.
37. Centers for Disease Control and Prevention. Incidence of acute hepatitis B-United States 1990-2002. MMWR 2004; 52:1252-1254.
38. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713-719.
39. Army Medical Surveillance Activity. Vaccine-preventable diseases, military members and other beneficiaries of the U.S. military health system 2005-2006. Medical Surveillance Monthly Report 2007; 13:13-17.
40. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh ZL, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991; 173:531-538.
41. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004; 326:20-28.
42. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-in-fected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310-1314.
43. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK. A STEP into darkness or light? Science 2008; 320:753-755.
44. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman NL, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multicenter efficacy trial among homosexual men. Ann Intern Med 1982; 97:362-366.
45. De Vries-Sluijs TEMS, Hansen BE, van Doornum GJJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197:292-294.
46. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229.
47. Ferrari C, Penna A, Giuberti T, Tong MJ, Ribera E, Fiaccadori F, Chisari FV. Intrahepatic, nucleocapsid antigen-specific T cells in chornic active hepatitis B. J Immunol 1987; 139:2050-2058.
48. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-1058.
49. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:3442-3449.
50. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/ HBV coinfection. J Infect Dis 2003; 188:1815-1819.
51. Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis 2005; 191:1169-1179.
52. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly R, Finkel TH. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992; 176:1099-1106.
53. Sheng W, Kao J, Chen P, Huang L, Chang S, Sun H, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-1229.
54. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vi-lar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two differentdoses. AIDS Res Ther 2006; 3:9.